-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Regeneron Pharmaceuticals, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from 2010 to 2024.
- Regeneron Pharmaceuticals, Inc. Earnings Per Share, Diluted for the quarter ending December 31, 2024 was 8.12 USD/shares, a 20.5% decline year-over-year.
- Regeneron Pharmaceuticals, Inc. Earnings Per Share, Diluted for the twelve months ending December 31, 2024 was 38.3 USD/shares, a 10.3% increase year-over-year.
- Regeneron Pharmaceuticals, Inc. annual Earnings Per Share, Diluted for 2024 was 38.3 USD/shares, a 10.3% increase from 2023.
- Regeneron Pharmaceuticals, Inc. annual Earnings Per Share, Diluted for 2023 was 34.8 USD/shares, a 9.03% decline from 2022.
- Regeneron Pharmaceuticals, Inc. annual Earnings Per Share, Diluted for 2022 was 38.2 USD/shares, a 46.9% decline from 2021.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Growth (%)